Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice – Results of the Non-Interventional DETECT Study

BACKGROUND: LABA (long-acting β2-agonists) and/or LAMA (long-acting muscarinic antagonists) represent the first treatment options for patients with symptomatic COPD. Although both display different mechanisms of activity, in combination they have a stronger broncho-dilating effect than monotherapy;...

Descripción completa

Detalles Bibliográficos
Autores principales: Plate, Tanja, Friedrich, Felix W, Beier, Jutta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293910/
https://www.ncbi.nlm.nih.gov/pubmed/32606643
http://dx.doi.org/10.2147/COPD.S252354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293910/
https://www.ncbi.nlm.nih.gov/pubmed/32606643
http://dx.doi.org/10.2147/COPD.S252354

Ejemplares similares